Suppr超能文献

通过将遗传配体插入不同的衣壳支架,腺病毒在体外和体内将癌症标志物EphA2用作受体。

Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

作者信息

Behr Michael, Kaufmann Johanna K, Ketzer Patrick, Engelhardt Sarah, Mück-Häusl Martin, Okun Pamela M, Petersen Gabriele, Neipel Frank, Hassel Jessica C, Ehrhardt Anja, Enk Alexander H, Nettelbeck Dirk M

机构信息

Oncolytic Adenovirus Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Max von Pettenkofer-Institute, Department of Virology, Ludwig-Maximilians-University Munich, Munich, Germany.

出版信息

PLoS One. 2014 Apr 23;9(4):e95723. doi: 10.1371/journal.pone.0095723. eCollection 2014.

Abstract

Adenoviral gene therapy and oncolysis would critically benefit from targeted cell entry by genetically modified capsids. This requires both the ablation of native adenovirus tropism and the identification of ligands that remain functional in virus context. Here, we establish cell type-specific entry of HAdV-5-based vectors by genetic ligand insertion into a chimeric fiber with shaft and knob domains of the short HAdV-41 fiber (Ad5T/41sSK). This fiber format was reported to ablate transduction in vitro and biodistribution to the liver in vivo. We show that the YSA peptide, binding to the pan-cancer marker EphA2, can be inserted into three positions of the chimeric fiber, resulting in strong transduction of EphA2-positive but not EphA2-negative cells of human melanoma biopsies and of tumor xenografts after intratumoral injection. Transduction was blocked by soluble YSA peptide and restored for EphA2-negative cells after recombinant EphA2 expression. The YSA peptide could also be inserted into three positions of a CAR binding-ablated HAdV-5 fiber enabling specific transduction; however, the Ad5T/41sSK format was superior in vivo. In conclusion, we establish an adenovirus capsid facilitating functional insertion of targeting peptides and a novel adenovirus using the tumor marker EphA2 as receptor with high potential for cancer gene therapy and viral oncolysis.

摘要

腺病毒基因治疗和溶瘤疗法将从通过基因改造衣壳实现靶向细胞进入中显著受益。这既需要消除天然腺病毒的嗜性,又需要鉴定在病毒环境中仍具功能的配体。在此,我们通过将遗传配体插入具有短HAdV-41纤维(Ad5T/41sSK)的轴和柄结构域的嵌合纤维中,建立了基于HAdV-5的载体的细胞类型特异性进入。据报道,这种纤维形式在体外可消除转导作用,并在体内改变生物分布,使其不向肝脏聚集。我们表明,与泛癌标志物EphA2结合的YSA肽可插入嵌合纤维的三个位置,在瘤内注射后,可使人黑色素瘤活检组织和肿瘤异种移植物中EphA2阳性而非EphA2阴性细胞发生强烈转导。可溶性YSA肽可阻断转导,重组EphA2表达后,EphA2阴性细胞的转导得以恢复。YSA肽也可插入消除了CAR结合能力的HAdV-5纤维的三个位置,实现特异性转导;然而,Ad5T/41sSK形式在体内表现更优。总之,我们构建了一种便于靶向肽功能插入的腺病毒衣壳,并构建了一种以肿瘤标志物EphA2为受体的新型腺病毒,在癌症基因治疗和病毒溶瘤方面具有很高的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/3997477/fdc48b5c209d/pone.0095723.g001.jpg

相似文献

2
Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo.
World J Gastroenterol. 2009 Jun 14;15(22):2754-62. doi: 10.3748/wjg.15.2754.
5
Peptide targeting of adenoviral vectors to augment tumor gene transfer.
Cancer Gene Ther. 2012 Jul;19(7):476-88. doi: 10.1038/cgt.2012.23. Epub 2012 May 18.
7
Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors.
Hum Gene Ther. 2002 Mar 20;13(5):613-26. doi: 10.1089/10430340252837215.
9
Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity.
Hum Gene Ther. 2005 Feb;16(2):248-61. doi: 10.1089/hum.2005.16.248.
10
Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.
Gene Ther. 2003 Jan;10(2):153-62. doi: 10.1038/sj.gt.3301845.

引用本文的文献

4
Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.
JCO Precis Oncol. 2021 Apr 27;5. doi: 10.1200/PO.21.00003. eCollection 2021.
5
Development of novel vaccine vectors: Chimpanzee adenoviral vectors.
Hum Vaccin Immunother. 2018 Jul 3;14(7):1679-1685. doi: 10.1080/21645515.2017.1419108. Epub 2018 Jan 23.
6
Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.
Virus Genes. 2017 Oct;53(5):692-699. doi: 10.1007/s11262-017-1498-z. Epub 2017 Jul 28.
7
A novel oncolytic adenovirus based on simian adenovirus serotype 24.
Oncotarget. 2017 Apr 18;8(16):26871-26885. doi: 10.18632/oncotarget.15845.
8
Progresses towards safe and efficient gene therapy vectors.
Oncotarget. 2015 Oct 13;6(31):30675-703. doi: 10.18632/oncotarget.5169.
9
Targeting the Eph System with Peptides and Peptide Conjugates.
Curr Drug Targets. 2015;16(10):1031-47. doi: 10.2174/1389450116666150727115934.

本文引用的文献

1
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.
Nat Med. 2013 Apr;19(4):452-7. doi: 10.1038/nm.3107. Epub 2013 Mar 24.
3
Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
J Invest Dermatol. 2013 Apr;133(4):1034-42. doi: 10.1038/jid.2012.459. Epub 2012 Dec 6.
5
T cells redirected to EphA2 for the immunotherapy of glioblastoma.
Mol Ther. 2013 Mar;21(3):629-37. doi: 10.1038/mt.2012.210. Epub 2012 Oct 16.
6
7
Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses.
Nucleic Acids Res. 2012 Nov;40(21):e167. doi: 10.1093/nar/gks734. Epub 2012 Aug 9.
8
Oncolytic virotherapy.
Nat Biotechnol. 2012 Jul 10;30(7):658-70. doi: 10.1038/nbt.2287.
10
Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.
Biomaterials. 2012 Feb;33(6):1838-50. doi: 10.1016/j.biomaterials.2011.11.020. Epub 2011 Dec 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验